Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AC-73 is an orally available Cluster of Differentiation 147 (CD147) inhibitor with high bioavailability that selectively disrupts the dimerization of CD147 (the binding site is in the N-terminal IgC2 domain of CD147 including Glu64 and Glu73), resulting in inhibition of the CD147/ERK1/2/STAT3/MMP-2 pathway and inhibition of liver cancer cell motility and invasion. AC-73 has antiproliferative activity and induces autophagy in leukemia cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 45.00 | |
5 mg | In stock | $ 98.00 | |
10 mg | In stock | $ 183.00 | |
25 mg | In stock | $ 322.00 | |
50 mg | In stock | $ 540.00 | |
100 mg | In stock | $ 957.00 | |
500 mg | In stock | $ 1,920.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 110.00 |
Description | AC-73 is an orally available Cluster of Differentiation 147 (CD147) inhibitor with high bioavailability that selectively disrupts the dimerization of CD147 (the binding site is in the N-terminal IgC2 domain of CD147 including Glu64 and Glu73), resulting in inhibition of the CD147/ERK1/2/STAT3/MMP-2 pathway and inhibition of liver cancer cell motility and invasion. AC-73 has antiproliferative activity and induces autophagy in leukemia cells. |
In vitro |
AC-73 (5-10 μM; 24 hours; SMMC-7721 and Huh-7 cells) treatment results in a dose-dependent reduction in the migration ability of SMMC-7721 and Huh-7 cells, as well as a dose-dependent decrease in the invasion of these two HCC cell lines at 24 hours. AC-73 treatment leads to a reduction in HCC metastasis. When treating the two HCC cell lines with AC-73 at a maximum concentration of 20 μM, there are no significant effects on cell viability. AC-73 potentially binds to CD147 at Glu64 and Glu73 in the N-terminal IgC2 domain, where both residues are situated within the dimer interface of CD147.[1] AC-73 (5-10 μM; 24 hours; SMMC-7721 cells), at a concentration of 10 μM, significantly inhibits the mRNA expression of both MMP-2 and MMP-9, with a more pronounced effect on MMP-2, while demonstrating no discernible impact on MMP-1, MMP-3, MMP-7, MMP-11, or MMP-13. AC-73 exhibits a dose-dependent reduction in MMP-2 mRNA levels and protein secretion, as confirmed through RT-qPCR analysis and gelatin zymography experiments.[1] AC-73 (5-20 μM; 6 hours; SMMC-7721 cells), in a dose-dependent manner, attenuates the phosphorylation of ERK1/2 and STAT3.[1] |
In vivo | AC-73 (25-50 mg/kg; Injected; daily; for 3 weeks; Male BALB/c nu/nu mice with SMMC-7721 cells) treatment significantly decreases the incidence of metastatic foci in nude mice. AC-73 inhibits the phosphorylation of ERK1/2 and STAT3 in a dose-dependent manner. MMP-2 is also reduced by AC-73. AC-73 could not inhibit tumor cell proliferation in vivo.[1] |
Molecular Weight | 319.4 |
Formula | C21H21NO2 |
CAS No. | 775294-71-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (313.09 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AC-73 775294-71-8 Autophagy AC 73 AC73 inhibitor inhibit